PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 297 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 9.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,093,169 | -25.6% | 263,793 | -2.8% | 0.01% | -14.3% |
| Q2 2023 | $10,873,036 | -6.3% | 271,351 | -4.6% | 0.01% | -12.5% |
| Q1 2023 | $11,606,323 | +3.1% | 284,399 | -2.4% | 0.01% | 0.0% |
| Q4 2022 | $11,253,927 | -30.9% | 291,477 | -4.8% | 0.01% | -38.5% |
| Q3 2022 | $16,289,000 | -19.2% | 306,240 | -11.4% | 0.01% | -13.3% |
| Q2 2022 | $20,156,000 | -22.7% | 345,743 | +1.2% | 0.02% | -6.2% |
| Q1 2022 | $26,084,000 | +19.7% | 341,768 | -5.7% | 0.02% | +23.1% |
| Q4 2021 | $21,796,000 | -0.8% | 362,236 | -7.7% | 0.01% | -7.1% |
| Q3 2021 | $21,969,000 | -7.0% | 392,302 | +0.7% | 0.01% | -6.7% |
| Q2 2021 | $23,634,000 | -16.4% | 389,476 | -3.4% | 0.02% | -25.0% |
| Q1 2021 | $28,267,000 | +19.4% | 403,309 | +2.0% | 0.02% | +11.1% |
| Q4 2020 | $23,666,000 | -6.4% | 395,482 | -6.0% | 0.02% | -14.3% |
| Q3 2020 | $25,291,000 | +25.8% | 420,673 | +9.8% | 0.02% | +16.7% |
| Q2 2020 | $20,110,000 | +60.3% | 383,271 | +2.5% | 0.02% | +28.6% |
| Q1 2020 | $12,542,000 | -28.2% | 374,052 | -2.9% | 0.01% | -6.7% |
| Q4 2019 | $17,458,000 | +22.6% | 385,386 | +3.0% | 0.02% | +15.4% |
| Q3 2019 | $14,243,000 | +712.0% | 374,112 | +827.6% | 0.01% | +550.0% |
| Q2 2019 | $1,754,000 | +258.0% | 40,330 | +212.9% | 0.00% | – |
| Q1 2019 | $490,000 | -4.9% | 12,888 | +7.8% | 0.00% | -100.0% |
| Q4 2018 | $515,000 | -13.3% | 11,961 | -1.1% | 0.00% | 0.0% |
| Q3 2018 | $594,000 | +162.8% | 12,094 | +66.8% | 0.00% | – |
| Q1 2018 | $226,000 | -55.9% | 7,250 | -35.5% | 0.00% | – |
| Q4 2017 | $512,000 | +96.2% | 11,236 | +105.6% | 0.00% | – |
| Q2 2017 | $261,000 | +10.1% | 5,466 | +5.2% | 0.00% | – |
| Q1 2017 | $237,000 | -8.1% | 5,196 | +6.8% | 0.00% | – |
| Q1 2016 | $258,000 | -46.6% | 4,867 | -22.5% | 0.00% | -100.0% |
| Q4 2015 | $483,000 | +87.2% | 6,284 | 0.0% | 0.00% | – |
| Q3 2015 | $258,000 | -41.9% | 6,284 | +0.1% | 0.00% | -100.0% |
| Q2 2015 | $444,000 | -24.4% | 6,277 | -5.0% | 0.00% | 0.0% |
| Q1 2015 | $587,000 | +0.7% | 6,608 | +0.4% | 0.00% | 0.0% |
| Q4 2014 | $583,000 | -20.9% | 6,580 | -13.4% | 0.00% | 0.0% |
| Q3 2014 | $737,000 | +8.1% | 7,601 | +2.4% | 0.00% | 0.0% |
| Q2 2014 | $682,000 | +12.0% | 7,421 | -14.8% | 0.00% | 0.0% |
| Q1 2014 | $609,000 | +20.6% | 8,706 | -0.9% | 0.00% | 0.0% |
| Q4 2013 | $505,000 | +37.2% | 8,789 | +14.8% | 0.00% | 0.0% |
| Q3 2013 | $368,000 | +38.3% | 7,658 | -16.4% | 0.00% | 0.0% |
| Q2 2013 | $266,000 | – | 9,156 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |